Introduction
The sustained-release intravitreal (IV) 0.7 mg dexamethasone (DEX) implant (Ozurdex ® , Allergan Pharmaceuticals, Irvine, CA, USA) is approved in Europe for the treatment of macular edema related to the following diseases: diabetic retinopathy, branch retinal vein occlusion or central retinal vein occlusion, and noninfectious uveitis. 1 DEX is one of the 3 most commonly used intraocular corticosteroids together with triamcinolone acetonide (TA) and fluocinolone acetonide. However, compared with these, DEX differs in its pharmacokinetics and pharmacodynamics properties due to certain biological effectiveness: different glucocorticoid receptor binding affinity (DEX . fluocinolone . triamcinolone) and different anti-inflammatory activities (DEX = fluocinolone and is 5 times more active than triamcinolone). 1, 2 The advantage of a DEX implant, containing micronized, preservative-free DEX 0.7 mg in a biodegradable copolymer of polylactic-co-glycolic acid (which eventually breaks down into carbon dioxide and water), is the release of the active ingredient within the vitreous chamber for up to 6 months after an IV injection. All these aforementioned features allow reduction in the frequency of injections with benefit in terms of hospital and patient resource saving, including diminished complications related to injection procedure (eg, retinal detachment, endophthalmitis, lens iatrogenic injury, etc). However, in real life it has been shown that a shorterinterval re-treatment is required because of the loss of the drug's effectiveness before 6 months, with a reported range varying from 4 to 5.9 months. 3, 4 Another relevant pharmacological aspect, as demonstrated by experimental studies, is the reduction of IV drugs half-life in vitrectomized eyes compared with non-vitrectomized ones, making their use ineffective. 5 On the contrary, DEX implant has the advantage of maintaining the same half-life and, therefore, the same pharmacological properties in both vitrectomized and nonvitrectomized eyes. [6] [7] [8] Regarding complications related to the use of DEX implant, pivotal studies and real-life studies have confirmed a good safety profile with only a few complications: cataract progression in the range from 29.8% 9 to 67.9%, 10 closely related to the number of implants received, and an increase of intraocular pressure (IOP) .10 mmHg from baseline reported in a range of 15.4% 9 and 27.7% 10 of cases. There are several reviews collecting literature data about the approved use of sustained-release DEX implants. However, there are various ocular pathologies with inflammatory etiopathogeneses associated with macular edema, such as: neovascular agerelated macular degeneration (nAMD); Irvine-Gass syndrome (IGS); vasoproliferative retinal tumors (VPRTs); retinal telangiectasia and Coats' disease; radiation maculopathy; retinitis pigmentosa; macular edema secondary to scleral buckling and pars plana vitrectomy (PPV), all of which have been treated by DEX implant.
The aim of this review was to provide a systematic collection of all of the diseases that benefit from the use of the sustained-release DEX implant alone or in combination with concomitant therapies in order to provide a valuable therapy option for these diseases in clinical practice.
Methods
MEDLINE databases for the period 2009 to September 2016 were searched by using the medical subject heading "Dexamethasone intravitreal implant/Ozurdex" and the keywords "macular edema, age-related macular degeneration, Irvine-Gass, pseudophakic cystoid macular edema, post-operative macular edema, PPV, scleral buckling, retinitis pigmentosa, prostaglandin, radiation macular edema, telangiectasia." Studies were limited to the English language. Because randomized controlled trials on these topics were lacking, all studies (retrospective and prospective, comparative and non-comparative, randomized and nonrandomized, single center and multicenter, and case reports) were analyzed. Aims, and anatomical and functional outcomes, and complications after DEX implant were analyzed.
nAMD
Approved first-line therapy for nAMD is based on the use of anti-vascular endothelial grow factor (VEGF) IV injections such as pegaptanib, ranibizumab, and aflibercept. However, there are patients who have a non-complete response to anti-VEGF injections as well as patients who, after an optimal functional and anatomical response, develop tachyphylaxis.
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The explanation for this incomplete response lies in the multifactorial pathogenesis of AMD, which involves VEGF, inflammation, and oxidative stress, as seen in histological studies performed on neovascular membranes after their surgical excision. Neovascular membrane growth in the subretinal space is stimulated by activated macrophages (and other inflammatory cells secreting cytokines) and enzymes that can damage the Bruch's membrane. 12 Therefore, inflammation is another potential target of nAMD treatment that could be counteracted by the use of corticosteroids.
Combination therapy consisting of anti-VEGF therapy and a corticosteroid relies on the use of drugs with different mechanisms of action, and could allow the reduction of anti-VEGF IV injection frequency and therefore, improve long-term efficacy and safety while reducing scarring results. [13] [14] [15] [16] Using combination therapies to treat nAMD dates back to photodynamic therapy (PDT), when it was associated with the IV TA injection. 17, 18 However, side effects due to IV TA, such as cataract progression and increased IOP, sometimes resistant to medical therapy, halted these procedures despite anatomical and functional benefits. 19 Cataract surgery has been reported in around 45.2% of eyes that underwent triamcinolone injection, 19 and ocular hypertension (IOP .21 mmHg) in around 44.6% of eyes, with IOP-lowering surgery required in 0.3% of eyes. 20 The LuceDex study 21 was the first study using the IV DEX injections (500 mg in 0.05 mL), followed by IV ranibizumab (4 monthly injections of 0.5 mg in 0.05 mL) that was compared with IV ranibizumab monotherapy (Group 2; total Drug Design, Development and Therapy 2017:11 submit your manuscript | www.dovepress.com
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DeX implant for the treatment of macular edema 37 patients). After 4 consecutive months, in both groups, ranibizumab pro re nata treatment was administered if signs of lesion activity were present. The results of this study showed a clear benefit for combination therapy, with reduction in the dimension of the choroidal neovascular membrane, detected by fluorescein angiography, improvement in visual acuity, and reduced treatment frequency. Central macular thickness (CMT) and volume reductions were also observed, although these changes were not statistically significant.
After the approval of the DEX implant, several authors evaluated its efficacy in nAMD [22] [23] [24] [25] (Table 1) . Compared with ranibizumab monotherapy, studies showed no long-term improvement of best corrected visual acuity (BCVA) and reduction of CMT; [22] [23] [24] [25] however, DEX implant in some cases allowed a reduced number of anti-VEGF injections. 23, 24 One study 24 reported an incidence of cataract surgery of 9% in ranibizumab-treated eyes and 33% in eyes receiving 2 DEX implants. The incidence of ocular hypertension ranged from 15% to 42%, [22] [23] [24] [25] all treated with topical hypotonizing therapy.
IGS
The most likely physiopathological hypothesis for IGS is an inflammatory response instigated by the inflammatory mediators released during and after surgical procedures, causing alterations to the blood-retinal barrier. Many risk factors have been identified, such as posterior capsule rupture and vitreous loss, as well as the use of iris retractors, the presence of an epiretinal membrane, a vein occlusion, a history of uveitis or diabetes and the use of prostaglandin eye drops. 26 First-line treatment for IGS involves the use of different therapies: topical nonsteroidal anti-inflammatory drugs (NSAIDs), oral acetazolamide, and topical corticosteroids. In patients resistant to such treatments, the following offlabel treatment options have been tried: [26] [27] [28] [29] [30] [31] [32] • IV anti-VEGF • Subcutaneous interferon α2a injections • IV infliximab (anti-tumor necrosis factor-α) • Intra-, retro-, and peribulbar corticosteroids • PPV Several authors have evaluated the efficacy of DEX implant for chronic IGS [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] (Table 2) . Most of the studies had a 6-month follow-up; they showed a significant improvement in BCVA and a significant reduction in CMT with 1 DEX implant. Two prospective studies 38, 43 of DEX compared with IVTA showed similar functional effects and anatomical effects: one found a lower incidence of ocular hypertension in the DEX group (at 6 months 0% vs 20%, P=0.044).
A retrospective long-term study 44 that included 58 cases of IGS in a total of 100 eyes found that efficacy was maintained at 24 months, after a mean number of 1.77 DEX implants in the first year and 1.70 in the second year. At 24 months, an IOP .25 mmHg was found in 6.2% of the patients, all treated with hypotensive eye drops and not requiring filtering surgery. 44 
VPRTs
Several approaches have been used to treat VPRTs, including cryotherapy, laser photocoagulation, PDT, IV anti-VEGF, plaque brachytherapy, and PPV. [45] [46] [47] VPRTs treated by DEX and PDT were reported in 3 cases 48 (Table 3) . Total involution of the tumor was reported within 2 months and regression of exudates continued for several months, leaving fibrotic scar tissue in the inferior half of the retina.
48
Retinal telangiectasia and Coats' disease Retinal telangiectasia
Yannuzzi et al 49 have recently classified different forms of idiopathic macular telangiectasia: aneurismal telangiectasia, idiopathic perifoveal telangiectasia, and occlusive telangiectasia. Although several approaches have been suggested for the treatment of idiopathic macular telangiectasia (including laser photocoagulation, 50 PDT, 51 IV anti-VEGF, 52 PPV 53 ), no treatment has yet been shown to provide a consistent effect on visual acuity. Also, corticosteroids have been used to treat these vascular pathologies due to their biological effect 54 and DEX implant can be assumed to be an useful therapeutic device, 55, 56 which can also be administered in pediatric patients 57 (Table 4) . In these cases, with a longer follow-up, multiple DEX implants were performed, at each time successfully (leading to BCVA improvement and CMT reduction).
56-58
Coats' disease
In Coats' disease, ablative therapy by laser photocoagulation and cryotherapy is the gold standard of treatment 57 with photocoagulation preferred over cryotherapy in cases with little or no subretinal fluid. 57 IV therapies such as anti-VEGF and steroids could be used to improve anatomic and visual outcomes, 58, 59 in particular, in combination with ablative therapies. IV corticosteroids, including DEX implant [60] [61] [62] Drug Design, Development and Therapy 2017:11 submit your manuscript | www.dovepress.com
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Bonfiglio et al have been used to reduce intraocular inflammation, tighten capillary walls, and suppress cell proliferation, also having anti-VEGF properties, 58 (Table 5 ). In one case, DEX implant led to a resolution of the exudative retinal detachment allowing laser photocoagulation of telangiectatic vessels. 63 In other cases, final BCVA was influenced by subfoveal fibrosis, present at the time of the treatment 58 or existing over a long-term.
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Radiation maculopathy
Several treatments have been proposed for radiation maculopathy, including laser photocoagulation, PDT, periocular injection of TA, IV anti-VEGF and, most recently, DEX implant (Table 6) . [63] [64] [65] [66] [67] [68] All of these studies demonstrated a significant anatomical benefit with DEX implant in cases of recalcitrant radiation macular edema, with significant changes in visual acuity in most of the cases. Two comparative studies 65, 67 comparing DEX implant with anti-VEGF therapy, found no difference in outcomes, and a reduction in the number of injections in DEX-treated eyes. 65 IOP increased in some eyes, 63, 64, 66 all successfully treated by topical hypotonizing therapy. Cataract development in these cases [64] [65] [66] could be caused by DEX or the radiation therapy.
Retinitis pigmentosa
The exact pathogenesis of macular edema, whether it is related to chronic and low-grade inflammatory process 69 or to autoimmune process as antiretinal antibodies 70 or to the failure of the retinal pigment epithelium pumping mechanism, is unknown as yet. 71 Treatments attempted include topical and systemic administration of CAI, 71 NSAIDs, retinal laser photocoagulation, vitrectomy surgery, 72 and IV anti-VEGF. 73 Also, IV corticosteroids injections have been performed as these drugs may modulate the inflammatory mediators and the autoimmune process. [74] [75] [76] The studies reporting on the use of DEX in macular edema related to retinitis pigmentosa consist of case report studies, which include only a few eyes (Table 7) . [77] [78] [79] [80] Nevertheless, an anatomical and functional improvement has been shown, but a relapse of macular edema occurred before 6 months from the implant 77 and an additional DEX was required in some cases. 77, 78 DEX implant proved to be safe with an IOP rise .21 mmHg recorded in only one eye. 
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Bonfiglio et al DEX implant in macular edema after retinal surgery DEX implant was used also in case of macular edema secondary to PPV for epiretinal membrane or macular hole or scleral buckling (Table 8) . [81] [82] [83] [84] [85] In all cases, an anatomical and functional improvement was shown, even though in 2 cases, multiple DEX implants were performed because of recurrent macular edema. 82 Additionally, the use of DEX allowed resolution of severe choroidal inflammation detected in 1 case following scleral buckle surgery. 85 
Conclusion
The use of DEX implant for all of the aforementioned macular pathologies merits consideration, and the results reported can support the use of DEX implant on a case-bycase basis with the aim of improving patient outcomes in many macular pathologies.
In many of these cases, DEX implant allowed a reduction of CMT with an improvement of BCVA, even if, at long term, many eyes required retreatment because DEX implant started to lose its efficacy, sometimes at 3 months after the injection.
Many of these cases were refractory to previous treatments, and DEX implant was administered as the last treatment option. Consequently, the functional results provided may be influenced by the lateness of DEX implant use. Therefore, considering that many of the reported macular pathologies may be difficult to treat and that some of them are not especially uncommon, having an awareness of a new treatment option and its influence on the clinical course of the disease may represent a great assistance in clinical practice. Furthermore, the use of DEX remains the only solution in treating macular edema in vitrectomized eyes where the efficacy of other IV drug injections, such as anti-VEGF, is lost due to their pharmacokinetic properties.
DEX implant-related adverse events in this expandinguse scenario are consistent with those previously documented for the DEX treatment of diabetic macular edema, uveitis, and retinal vein occlusion. 10, 86, 87 In the cases that we analyzed, cataract was reported in up to 33% of the eyes after 2 DEX implants, 24 and the occurrence of ocular hypertension (IOP $25 mmHg) from 6% 38 to 31%, 32 all treated with topical therapy.
In conclusion, DEX implant may allow less frequent anti-VEGF treatment 24, 65 and therefore, the advantages for the patient are clear: the need to undergo stressful treatment is removed while ocular and systemic adverse effects are reduced.
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